Jonathan Bennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan Bennett has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Thomas A. Treibel
Barts Heart Centre, St Bartholomew’s Hospital , London
8 shared publications - George D. Thornton
University College London , 62 Huntley Street, London WC1E 6DD
6 shared publications - Alun David Hughes
Institute of Cardiovascular Science, University College London, London, UK
5 shared publications - Christian Nitsche
Medical University of Vienna
4 shared publications - James Charles Moon
MyCardium AI Imaging Core Lab, Institute of Cardiovascular Science, University College London and Barts Heart Centre, St Bartholomew's Hospital, London, UK
4 shared publications - Nikoo Aziminia
Institute of Cardiovascular Science, University College London, London, United Kingdom; Department of Cardiovascular Imaging, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom
4 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (12)
Life-Course Blood Pressure Trajectories and Focal Myocardial Fibrosis in Older Age in MyoFit46
BACKGROUND: The impact of life-course blood pressure (BP) trajectories on later-life focal left ventricular (LV) fibrosis by late gadolinium enhancement (LGE) remains elusive. METHODS: MyoFit46 prospectively recruited ≈500 participants from the 1946 National Survey of Health and Development birth cohort for a cardiovascular magnetic resonance scan at 77 years, assessing LV LGE mass (in grams), calculated using the 3-SD (LGE 3SD ) or 5-SD (LGE 5SD ) methods. Cross-sectional systolic (SBPs) and diastolic BPs (DBPs) were recorded at 36, 43, 53, 63, 69, and 77 years. For each participant and age interval, annual rates of BP change (steepness) were calculated using the observed BPs, and areas under the BP trajectory curve (cumulative burden) were derived using mixed-effects models. Associations between life-course BPs and LV LGE were tested using generalized linear models, adjusted for antihypertensives, demographics, lifestyle, and comorbidities. Time-to-event associations between LV LGE and incident major adverse cardiovascular events (MACE = hospitalizations for coronary artery disease, stroke, heart failure, and atrial/ventricular arrhythmias; N=29 events) were also evaluated. RESULTS: Among 472 participants (54% were men), each 10 mm Hg increment in cross-sectional SBPs at 36 to 69 years was associated with 6% to 11% greater LV LGE 3SD (all P ≤0.033), whereas each sustained 10 mm Hg greater SBP over any age interval from 36 to 69 was associated with 16% to 24% greater LV LGE 3SD at 77 years (all P ≤0.005), with all associations independent of SBP at 77 years. Each 1 mm Hg/y steeper SBP rise during age intervals 36 to 43, 43 to 53, and 53 to 63 years was associated with 6% to 12% greater LV LGE 3SD at 77 years. Results were similar if LV LGE 5SD was used instead. Fewer associations were significant for DBPs. The qualitative presence of LV LGE was associated with greater incident MACE rates (hazard ratio, 2.5 [95% CI, 1.2–5.2]). CONCLUSIONS: Higher life-course cross-sectional BPs, greater cumulative burden, and steeper BP increases were associated with greater LV LGE burden in older age, which was linked to incident MACE. BP trajectories, beyond single-point BP measurements, warrant further investigation as tools to guide BP management strategies.
- 1 December 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (12)
Open AccessLife-Course Blood Pressure Trajectories and Focal Myocardial Fibrosis in Older Age in MyoFit46
BACKGROUND: The impact of life-course blood pressure (BP) trajectories on later-life focal left ventricular (LV) fibrosis by late gadolinium enhancement (LGE) remains elusive. METHODS: MyoFit46 prospectively recruited ≈500 participants from the 1946 National Survey of Health and Development birth cohort for a cardiovascular magnetic resonance scan at 77 years, assessing LV LGE mass (in grams), calculated using the 3-SD (LGE 3SD ) or 5-SD (LGE 5SD ) methods. Cross-sectional systolic (SBPs) and diastolic BPs (DBPs) were recorded at 36, 43, 53, 63, 69, and 77 years. For each participant and age interval, annual rates of BP change (steepness) were calculated using the observed BPs, and areas under the BP trajectory curve (cumulative burden) were derived using mixed-effects models. Associations between life-course BPs and LV LGE were tested using generalized linear models, adjusted for antihypertensives, demographics, lifestyle, and comorbidities. Time-to-event associations between LV LGE and incident major adverse cardiovascular events (MACE = hospitalizations for coronary artery disease, stroke, heart failure, and atrial/ventricular arrhythmias; N=29 events) were also evaluated. RESULTS: Among 472 participants (54% were men), each 10 mm Hg increment in cross-sectional SBPs at 36 to 69 years was associated with 6% to 11% greater LV LGE 3SD (all P ≤0.033), whereas each sustained 10 mm Hg greater SBP over any age interval from 36 to 69 was associated with 16% to 24% greater LV LGE 3SD at 77 years (all P ≤0.005), with all associations independent of SBP at 77 years. Each 1 mm Hg/y steeper SBP rise during age intervals 36 to 43, 43 to 53, and 53 to 63 years was associated with 6% to 12% greater LV LGE 3SD at 77 years. Results were similar if LV LGE 5SD was used instead. Fewer associations were significant for DBPs. The qualitative presence of LV LGE was associated with greater incident MACE rates (hazard ratio, 2.5 [95% CI, 1.2–5.2]). CONCLUSIONS: Higher life-course cross-sectional BPs, greater cumulative burden, and steeper BP increases were associated with greater LV LGE burden in older age, which was linked to incident MACE. BP trajectories, beyond single-point BP measurements, warrant further investigation as tools to guide BP management strategies.
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (3)
Aortic valve assessment by cardiovascular magnetic resonance
- 2 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (3)
Open AccessAortic valve assessment by cardiovascular magnetic resonance
- Open Access
- 5 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (12) , 1829-1839
Myocardial remodelling in aortic regurgitation: time to think beyond volumes and function?
Current guideline criteria for surgical intervention in chronic aortic regurgitation (AR) rely on fixed thresholds of left ventricular size and ejection fraction, but these metrics may overlook early myocardial injury and under-appreciate patient heterogeneity, particularly in women and older adults. Cardiovascular magnetic resonance (CMR) offers robust quantification of regurgitant volume, three-dimensional ventricular volumes, and both focal (late gadolinium enhancement) and diffuse (T1-mapping–derived extracellular volume) fibrosis. Observational studies have linked CMR-detected fibrosis to worse clinical outcomes and less favourable reverse remodelling after valve intervention, suggesting that fibrosis may mark the transition from compensated overload to irreversible myocardial damage. In this narrative review, we appraise the limitations of current guidelines, compare echocardiographic and CMR approaches to AR assessment, and summarize the evidence supporting myocardial fibrosis as a potential imaging biomarker for risk stratification. We discuss how integrating CMR-derived fibrosis metrics with volumetric and functional data could personalize timing of aortic valve intervention. While prospective studies are needed to validate fibrosis-guided decision-making, this evolving paradigm holds promise for earlier identification of patients at risk for irreversible myocardial injury, with the ultimate goal of preserving ventricular function and improving long-term outcomes.
- 5 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (12) , 1829-1839
Open AccessMyocardial remodelling in aortic regurgitation: time to think beyond volumes and function?
Current guideline criteria for surgical intervention in chronic aortic regurgitation (AR) rely on fixed thresholds of left ventricular size and ejection fraction, but these metrics may overlook early myocardial injury and under-appreciate patient heterogeneity, particularly in women and older adults. Cardiovascular magnetic resonance (CMR) offers robust quantification of regurgitant volume, three-dimensional ventricular volumes, and both focal (late gadolinium enhancement) and diffuse (T1-mapping–derived extracellular volume) fibrosis. Observational studies have linked CMR-detected fibrosis to worse clinical outcomes and less favourable reverse remodelling after valve intervention, suggesting that fibrosis may mark the transition from compensated overload to irreversible myocardial damage. In this narrative review, we appraise the limitations of current guidelines, compare echocardiographic and CMR approaches to AR assessment, and summarize the evidence supporting myocardial fibrosis as a potential imaging biomarker for risk stratification. We discuss how integrating CMR-derived fibrosis metrics with volumetric and functional data could personalize timing of aortic valve intervention. While prospective studies are needed to validate fibrosis-guided decision-making, this evolving paradigm holds promise for earlier identification of patients at risk for irreversible myocardial injury, with the ultimate goal of preserving ventricular function and improving long-term outcomes.
- Open Access
Metabolic profiling and longitudinal changes in patients with severe aortic stenosis undergoing valve replacement
Aims: In patients with aortic stenosis (AS), the relation of cardiac energetic pathways with cardiac structure and function, their changes, and their prognostic significance are not well understood. We aimed to characterise metabolic profiles in patients with severe AS before and after aortic valve replacement (AVR) and their association with functional status, structural remodelling and mortality. Methods and results: Patients with symptomatic, severe AS before (n=143) and 1-year after (n=113) AVR underwent cardiac magnetic resonance (CMR), serum cardiac biomarkers, and 6-minute walk test. Resting non-fasting plasma samples underwent targeted nuclear magnetic resonance for free fatty acids (FFAs), branched chain amino acids (BCAAs), glycolysis-related metabolites, and ketones. Lower FFAs and BCAA concentrations, but not glycolysis metabolites or ketones, correlated with greater myocardial mass and focal fibrosis, NT-proBNP, TnT and 6-minute walk distance. After 10.5 years of follow-up (66/143 deaths), lower FFAs and BCAAs, but not ketones were independently associated with higher mortality risk ( P <0.05). At 1-year after AVR, FFAs had decreased compared to baseline. Conclusion: Reduced serum FFAs and BCAA concentrations are cardiac, maladaptive metabolic changes to AS, and are not reversible after AVR. Whether these markers may be used to guide the timing of AVR or may be targeted by metabolic interventions remains to be evaluated by future research. Condensed In patients with aortic stenosis (AS) systemic metabolomics and their association with myocardial remodeling and outcome after aortic valve replacement (AVR) are largely unknown. We show that in severe AS low levels of unsaturated fatty acids and branch chain amino acids correlate with worse disease markers by cardiac magnetic resonance, biomarkers, and functional incapacity, do not increase after AVR and correlate with higher mortality. Targeted manipulation of metabolite perturbations might ameliorate myocardial energetics before and after AVR. Graphical Metabolites in severe aortic stenosis and their associations with cardiac remodeling/damage and mortality after aortic valve replacement (AVR). FFAs indicates free fatty acids; BCAA, branched chained amino acids;
Open AccessMetabolic profiling and longitudinal changes in patients with severe aortic stenosis undergoing valve replacement
Aims: In patients with aortic stenosis (AS), the relation of cardiac energetic pathways with cardiac structure and function, their changes, and their prognostic significance are not well understood. We aimed to characterise metabolic profiles in patients with severe AS before and after aortic valve replacement (AVR) and their association with functional status, structural remodelling and mortality. Methods and results: Patients with symptomatic, severe AS before (n=143) and 1-year after (n=113) AVR underwent cardiac magnetic resonance (CMR), serum cardiac biomarkers, and 6-minute walk test. Resting non-fasting plasma samples underwent targeted nuclear magnetic resonance for free fatty acids (FFAs), branched chain amino acids (BCAAs), glycolysis-related metabolites, and ketones. Lower FFAs and BCAA concentrations, but not glycolysis metabolites or ketones, correlated with greater myocardial mass and focal fibrosis, NT-proBNP, TnT and 6-minute walk distance. After 10.5 years of follow-up (66/143 deaths), lower FFAs and BCAAs, but not ketones were independently associated with higher mortality risk ( P <0.05). At 1-year after AVR, FFAs had decreased compared to baseline. Conclusion: Reduced serum FFAs and BCAA concentrations are cardiac, maladaptive metabolic changes to AS, and are not reversible after AVR. Whether these markers may be used to guide the timing of AVR or may be targeted by metabolic interventions remains to be evaluated by future research. Condensed In patients with aortic stenosis (AS) systemic metabolomics and their association with myocardial remodeling and outcome after aortic valve replacement (AVR) are largely unknown. We show that in severe AS low levels of unsaturated fatty acids and branch chain amino acids correlate with worse disease markers by cardiac magnetic resonance, biomarkers, and functional incapacity, do not increase after AVR and correlate with higher mortality. Targeted manipulation of metabolite perturbations might ameliorate myocardial energetics before and after AVR. Graphical Metabolites in severe aortic stenosis and their associations with cardiac remodeling/damage and mortality after aortic valve replacement (AVR). FFAs indicates free fatty acids; BCAA, branched chained amino acids;
- Open Access
Hydraulic forces assist left ventricular filling in aortic stenosis and improve after valve replacement in patients with the lowest hydraulic force and otherwise healthiest left ventricles at baseline
Background: Diastolic dysfunction in the setting of aortic valve replacement (AVR) for aortic stenosis (AS) is incompletely understood. This study aims to to assess the net hydraulic force of left ventricular (LV) filling in participants with severe symptomatic AS undergoing AVR. Methods: This single-centre prospective observational cohort study evaluated patients with severe, symptomatic AS undergoing AVR between 2012-2015. Clinical assessment and cardiovascular magnetic resonance (CMR) was completed prior to AVR and 1-year post-operatively. Atrioventricular area difference (AVAD) was used as a surrogate for the hydraulic force of LV filling. AVAD at mid-diastole was measured as the difference between LV short-axis area and left atrial short-axis area. Results: In patients with AS (n=110, 54% male, age 71 [64–77] years, aortic valve area 0.74±0.25 cm 2 ), AVAD was positive at baseline (2.8±6.5 cm 2 ) consistent with a net hydraulic force assisting LV filling. While AVAD did not change post-operatively on a group level (p=0.70), an improvement in AVAD was associated univariably with increasing baseline LV ejection fraction, and decreasing baseline AVAD, LV volume, mass, myocardial extracellular volume, and infarct size (p2 =0.49, p<0.001). Conclusion: In severe AS, hydraulic force contributes to LV filling prior to and following AVR. The greatest improvement in hydraulic force following AVR occurred in those with the lowest baseline hydraulic force, but also with lower age and the absence of otherwise deleterious LV myocardial remodelling, thus supporting the benefits of early intervention.
Open AccessHydraulic forces assist left ventricular filling in aortic stenosis and improve after valve replacement in patients with the lowest hydraulic force and otherwise healthiest left ventricles at baseline
Background: Diastolic dysfunction in the setting of aortic valve replacement (AVR) for aortic stenosis (AS) is incompletely understood. This study aims to to assess the net hydraulic force of left ventricular (LV) filling in participants with severe symptomatic AS undergoing AVR. Methods: This single-centre prospective observational cohort study evaluated patients with severe, symptomatic AS undergoing AVR between 2012-2015. Clinical assessment and cardiovascular magnetic resonance (CMR) was completed prior to AVR and 1-year post-operatively. Atrioventricular area difference (AVAD) was used as a surrogate for the hydraulic force of LV filling. AVAD at mid-diastole was measured as the difference between LV short-axis area and left atrial short-axis area. Results: In patients with AS (n=110, 54% male, age 71 [64–77] years, aortic valve area 0.74±0.25 cm 2 ), AVAD was positive at baseline (2.8±6.5 cm 2 ) consistent with a net hydraulic force assisting LV filling. While AVAD did not change post-operatively on a group level (p=0.70), an improvement in AVAD was associated univariably with increasing baseline LV ejection fraction, and decreasing baseline AVAD, LV volume, mass, myocardial extracellular volume, and infarct size (p2 =0.49, p<0.001). Conclusion: In severe AS, hydraulic force contributes to LV filling prior to and following AVR. The greatest improvement in hydraulic force following AVR occurred in those with the lowest baseline hydraulic force, but also with lower age and the absence of otherwise deleterious LV myocardial remodelling, thus supporting the benefits of early intervention.
- Open Access
- 1 December 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (12) , e017425
Left Ventricular Hypertrophy in Aortic Stenosis: Early Cell and Matrix Regression 2 Months Post-Aortic Valve Replacement
BACKGROUND: In aortic stenosis, the myocardium responds with left ventricular hypertrophy, which is characterized by increased left ventricular mass due to cellular hypertrophy and extracellular matrix expansion. Following aortic valve replacement (AVR), left ventricular hypertrophy regression occurs, but early cellular and extracellular dynamics are unknown. METHODS: Patients with severe symptomatic aortic stenosis undergoing surgical or transcatheter AVR were prospectively recruited. Pre- and early post-AVR cardiac magnetic resonance imaging assessed left ventricular remodeling, global longitudinal strain, and T1 mapping to determine extracellular volume fraction and volume of cellular and extracellular compartments. RESULTS: In all, 39 patients (aged 71.4±9.8 years, male 79%, aortic valve peak velocity 4.4±0.5 m/s) underwent cardiac magnetic resonance before and at median 7.7 weeks post-AVR. Left ventricular mass index reduced significantly by 15.4% ( P P P P 0.05). The asterisk in P values indicates a statistical significance of <0.05. CONCLUSIONS: Within 8 weeks of AVR for aortic stenosis, substantial left ventricular hypertrophy regression occurs involving both cellular and extracellular compartments, demonstrating the early myocardial adaptability to afterload relief. Cellular compartment regression is greater than extracellular regression, leading to an apparent increase in extracellular volume fraction. Mode of intervention did not affect degree of reverse remodeling, indicating that both are effective at resulting beneficial changes post-AVR. REGISTRATION: URL: https://www.isrctn.com ; Unique identifier: NCT04627987.
- 1 December 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (12) , e017425
Open AccessLeft Ventricular Hypertrophy in Aortic Stenosis: Early Cell and Matrix Regression 2 Months Post-Aortic Valve Replacement
BACKGROUND: In aortic stenosis, the myocardium responds with left ventricular hypertrophy, which is characterized by increased left ventricular mass due to cellular hypertrophy and extracellular matrix expansion. Following aortic valve replacement (AVR), left ventricular hypertrophy regression occurs, but early cellular and extracellular dynamics are unknown. METHODS: Patients with severe symptomatic aortic stenosis undergoing surgical or transcatheter AVR were prospectively recruited. Pre- and early post-AVR cardiac magnetic resonance imaging assessed left ventricular remodeling, global longitudinal strain, and T1 mapping to determine extracellular volume fraction and volume of cellular and extracellular compartments. RESULTS: In all, 39 patients (aged 71.4±9.8 years, male 79%, aortic valve peak velocity 4.4±0.5 m/s) underwent cardiac magnetic resonance before and at median 7.7 weeks post-AVR. Left ventricular mass index reduced significantly by 15.4% ( P P P P 0.05). The asterisk in P values indicates a statistical significance of <0.05. CONCLUSIONS: Within 8 weeks of AVR for aortic stenosis, substantial left ventricular hypertrophy regression occurs involving both cellular and extracellular compartments, demonstrating the early myocardial adaptability to afterload relief. Cellular compartment regression is greater than extracellular regression, leading to an apparent increase in extracellular volume fraction. Mode of intervention did not affect degree of reverse remodeling, indicating that both are effective at resulting beneficial changes post-AVR. REGISTRATION: URL: https://www.isrctn.com ; Unique identifier: NCT04627987.
- Open Access
- 4 July 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (1) , 271-272
Safety of ward-based, non-physician-led, cardiac monitor implantation
- 4 July 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (1) , 271-272
Open AccessSafety of ward-based, non-physician-led, cardiac monitor implantation
- Open Access
Assessment of Microvascular Disease in Heart and Brain by MRI: Application in Heart Failure with Preserved Ejection Fraction and Cerebral Small Vessel Disease
The objective of this review is to investigate the commonalities of microvascular (small vessel) disease in heart failure with preserved ejection fraction (HFpEF) and cerebral small vessel disease (CSVD). Furthermore, the review aims to evaluate the current magnetic resonance imaging (MRI) diagnostic techniques for both conditions. By comparing the two conditions, this review seeks to identify potential opportunities to improve the understanding of both HFpEF and CSVD.
Open AccessAssessment of Microvascular Disease in Heart and Brain by MRI: Application in Heart Failure with Preserved Ejection Fraction and Cerebral Small Vessel Disease
The objective of this review is to investigate the commonalities of microvascular (small vessel) disease in heart failure with preserved ejection fraction (HFpEF) and cerebral small vessel disease (CSVD). Furthermore, the review aims to evaluate the current magnetic resonance imaging (MRI) diagnostic techniques for both conditions. By comparing the two conditions, this review seeks to identify potential opportunities to improve the understanding of both HFpEF and CSVD.
- Open Access
- 4 March 2023
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 21 (3) , 193-210
Heart failure and excess mortality after aortic valve replacement in aortic stenosis
In aortic stenosis (AS), the heart transitions from adaptive compensation to an AS cardiomyopathy and eventually leads to decompensation with heart failure. Better understanding of the underpinning...
- 4 March 2023
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 21 (3) , 193-210
Open AccessHeart failure and excess mortality after aortic valve replacement in aortic stenosis
In aortic stenosis (AS), the heart transitions from adaptive compensation to an AS cardiomyopathy and eventually leads to decompensation with heart failure. Better understanding of the underpinning...
- Open Access
- 16 January 2023
- Published by S. Karger AG in Cerebrovascular Diseases Extra
- Vol. 13 (1) , 18-32
Evaluation of Microvascular Rarefaction in Vascular Cognitive Impairment and Heart Failure (CRUCIAL): Study Protocol for an Observational Study
Introduction: Microvascular rarefaction, the functional reduction in perfused microvessels and structural reduction of microvascular density, seems to be an important mechanism in the pathophysiology of small blood vessel-related disorders including vascular cognitive impairment (VCI) due to cerebral small vessel disease and heart failure with preserved ejection fraction (HFpEF). Both diseases share common risk factors including hypertension, diabetes mellitus, obesity, and ageing; in turn, these comorbidities are associated with microvascular rarefaction. Our consortium aims to investigate novel non-invasive tools to quantify microvascular health and rarefaction in both organs, as well as surrogate biomarkers for cerebral and/or cardiac rarefaction (via sublingual capillary health, vascular density of the retina, and RNA content of circulating extracellular vesicles), and to determine whether microvascular density relates to disease severity. Methods: The clinical research program of CRUCIAL consists of four observational cohort studies. We aim to recruit 75 VCI patients, 60 HFpEF patients, 60 patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement as a pressure overload HFpEF model, and 200 elderly participants with mixed comorbidities to serve as controls. Data collected will include medical history, physical examination, cognitive testing, advanced brain and cardiac MRI, ECG, echocardiography, sublingual capillary health, optical coherence tomography angiography (OCTa), extracellular vesicles RNA analysis, and myocardial remodelling-related serum biomarkers. The AS cohort undergoing surgery will also have myocardial biopsy for histological microvascular assessment. Discussion: CRUCIAL will examine the pathophysiological role of microvascular rarefaction in VCI and HFpEF using advanced brain and cardiac MRI techniques. Furthermore, we will investigate surrogate biomarkers for non-invasive, faster, easier, and cheaper assessment of microvascular density since these are more likely to be disseminated into widespread clinical practice. If microvascular rarefaction is an early marker of developing small vessel diseases, then measuring rarefaction may allow preclinical diagnosis, with implications for screening, risk stratification, and prevention. Further knowledge of the relevance of microvascular rarefaction and its underlying mechanisms may provide new avenues for research and therapeutic targets.
- 16 January 2023
- Published by S. Karger AG in Cerebrovascular Diseases Extra
- Vol. 13 (1) , 18-32
Open AccessEvaluation of Microvascular Rarefaction in Vascular Cognitive Impairment and Heart Failure (CRUCIAL): Study Protocol for an Observational Study
Introduction: Microvascular rarefaction, the functional reduction in perfused microvessels and structural reduction of microvascular density, seems to be an important mechanism in the pathophysiology of small blood vessel-related disorders including vascular cognitive impairment (VCI) due to cerebral small vessel disease and heart failure with preserved ejection fraction (HFpEF). Both diseases share common risk factors including hypertension, diabetes mellitus, obesity, and ageing; in turn, these comorbidities are associated with microvascular rarefaction. Our consortium aims to investigate novel non-invasive tools to quantify microvascular health and rarefaction in both organs, as well as surrogate biomarkers for cerebral and/or cardiac rarefaction (via sublingual capillary health, vascular density of the retina, and RNA content of circulating extracellular vesicles), and to determine whether microvascular density relates to disease severity. Methods: The clinical research program of CRUCIAL consists of four observational cohort studies. We aim to recruit 75 VCI patients, 60 HFpEF patients, 60 patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement as a pressure overload HFpEF model, and 200 elderly participants with mixed comorbidities to serve as controls. Data collected will include medical history, physical examination, cognitive testing, advanced brain and cardiac MRI, ECG, echocardiography, sublingual capillary health, optical coherence tomography angiography (OCTa), extracellular vesicles RNA analysis, and myocardial remodelling-related serum biomarkers. The AS cohort undergoing surgery will also have myocardial biopsy for histological microvascular assessment. Discussion: CRUCIAL will examine the pathophysiological role of microvascular rarefaction in VCI and HFpEF using advanced brain and cardiac MRI techniques. Furthermore, we will investigate surrogate biomarkers for non-invasive, faster, easier, and cheaper assessment of microvascular density since these are more likely to be disseminated into widespread clinical practice. If microvascular rarefaction is an early marker of developing small vessel diseases, then measuring rarefaction may allow preclinical diagnosis, with implications for screening, risk stratification, and prevention. Further knowledge of the relevance of microvascular rarefaction and its underlying mechanisms may provide new avenues for research and therapeutic targets.